Novel PCSK9 Inhibitor Recaticimab Lowers Lipids With Less Frequent Shots

(MedPage Today) -- PHILADELPHIA -- A novel anti-PCSK9 monoclonal antibody with a distinctive longer duration of action reduced cholesterol and other lipids in the phase III REMAIN-2 trial. Recaticimab showed long-term efficacy as an add-on treatment...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news